

FOR IMMEDIATE RELEASE

Fairway, KS

June 29, 2016

## IGXBio ANNOUNCES NEW CEO

David Foster, PhD, JD has been appointed as President and CEO of IGXBio, Inc. Making the announcement was James Laufenberg, the former CEO who will now become the Executive Chairman. Mr. Laufenberg stated, " I am very pleased that Dr. Foster has accepted his new role in the company. David came on board as a Director of the Company and rapidly demonstrated his ability to address key issues for day to day implementation".

Dr. Foster is a co-founder of two biotechnology companies, Tuevol Therapeutics and FPRT Bio. He has more than 17 years legal experience working as patent counsel in international law firms as well as in-house at Medarex, a biopharmaceutical company acquired by Bristol-Myers Squibb. David has developed and implemented international intellectual property (IP) strategies that protect and complement business initiatives. In addition he has identified foundational and complementary IP and coordinated licensing programs to supplement IP strategies for numerous products. David currently serves as Board secretary of BioNorthTx, a regional life science trade association he co-founded. David received his Ph.D. from The University of Texas Southwestern Medical Center and J.D. from Golden Gate University School of Law.

### About IGXBio

IGXBio, Inc. is a clinical stage biotechnology company developing advanced DNA immunotherapies for HIV infection. The Company's lead product candidate, GenePro<sup>®</sup>, is a DNA therapeutic incorporating a proprietary DNA composition that yields high levels of gene expression and non-infectious HIV protein production, and induces a robust antibody and cellular immune response in animal models, including non-human primates.

The Company has completed a comprehensive non-clinical and clinical development plan for GenePro<sup>®</sup>, and has achieved an IND.

The Company's organizational structure consists of a highly qualified and experienced team with complimentary expertise in clinical research, biopharmaceutical development, strategic planning, finance, law, and business operations. A Scientific Advisory Board and Board of Directors comprise this team.

For more information please contact:

Jim Laufenberg

[jim@igxbio.com](mailto:jim@igxbio.com)

General information

[info@igxbio.com](mailto:info@igxbio.com)